Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2011, Article ID 638020, 4 pages
Case Report

Lenalidomide-Associated ITP

1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
2Stem Cell Therapy, Duke University Medical Center, Durham, NC 27710, USA
3Division of Hematology, Duke University Medical Center, Durham, NC 27710, USA

Received 27 April 2011; Accepted 25 May 2011

Academic Editors: M.-C. Kyrtsonis, T. Sonoki, S. Storti, J. Várkonyi, and S. D. Wagner

Copyright © 2011 Christina I. Herold et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.